Home » Otsuka: Phase III Trial Meets Efficacy Criteria
Otsuka: Phase III Trial Meets Efficacy Criteria
Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced Tuesday that an independent data monitoring committee has recommended the early termination of its Phase 3, 52-week, placebo-controlled, intramuscular depot aripiprazole trial.
FreshNews
FreshNews
Upcoming Events
-
07May
-
14May
-
30May